SBC

SBC (Schweitzer Biotech Company) is a Taiwan-based "science incubator" built on decades of biotech execution. Growing from animal-health diagnostics & vaccines into a multi-vertical group spanning human vaccines, regenerative medicine (cell therapeutics/exosomes), clinically validated aesthetics, nutritional supplements, and scalable biomanufacturing platforms.

SBC is now a biotech juggernaut, with a major pillar being its human injectables and stem cell therapeutics companies. SBC has a long clinical-development track record and global public-health collaborations. During the COVID-19 pandemic, they were one of the few companies to develop an effective vaccine that was approved in record time. The group collectively employs more than 60 PhDs, becoming an R&D powerhouse with more than 300 peer-reviewed scientific publications, including those in the Lancet and Nature.

With more than 40 years of experience in the development, production, and registration of vaccines for animal diseases, SBC takes pride in providing its global customers with breakthrough technologies to accomplish their goals and strengthen their market position. SBC has collaborated with the world’s top 10 animal health companies and built an excellent reputation in animal disease prevention and control. SBC’s customer base spans over 3 continents and 8 different countries.